Hub : Traits :

Medication for cholesterol

21 significantly associated models · 15 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 109126153 110517617 1 1 3.2e-07 3.8e-07 1.0e+00 100 PSRC1
2 3 10617048 12293966 1 1 2.1e-07 5.3e-08 5.8e-02 88 ATG7
3 4 103091730 104503936 1 1 2.0e-07 1.5e-06 7.8e-01 100 CISD2
4 6 160071844 161571560 1 1 6.7e-08 8.8e-08 3.9e-02 85 SLC22A3
5 7 129917130 131315092 1 1 2.4e-07 5.2e-08 5.8e-03 74 RP11-138A9.1
6 11 1242690 2640824 1 1 2.7e-08 6.6e-09 2.7e-02 86 TNNT3
7 11 99859184 101559718 2 1 7.1e-08 1.9e-07 6.3e-01 99 TMEM133
8 11 106500377 108027561 1 1 4.0e-07 8.0e-06 8.2e-02 85 CWF19L2
9 12 111154626 112582540 1 1 1.5e-07 2.0e-11 1.4e-05 58 SH2B3
10 16 3969463 5510848 3 1 4.8e-09 6.3e-08 9.7e-03 77 MGRN1
11 16 89281093 90172696 1 1 2.9e-07 8.0e-06 1.3e-02 69 MC1R
12 19 48505468 49906278 1 1 1.2e-07 4.3e-07 1.2e-01 91 FUT2

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Crohns Disease (2017) 2.09 1 1 3.0 0.00 1.0e+00 FUT2
Irritable Bowel Disease (IBD) 1.63 2 0 0.0 0.00 1.0e+00 FUT2 SH2B3
Ulcerative Colitis (UC) 1.41 1 0 0.0 0.00 1.0e+00 CISD2
Reaction Time 2.29 1 1 3.0 0.00 1.0e+00 SH2B3
Breast Cancer 4.39 1 1 3.0 0.00 1.0e+00 TNNT3
Body Mass Index (BMI) (2010) 1.91 1 0 0.0 0.00 1.0e+00 SH2B3
Coronary Artery Disease (CAD) 6.50 3 1 3.0 0.00 1.0e+00 PSRC1 SH2B3 SLC22A3
Crohns Disease (2012) 1.78 1 0 0.0 0.00 1.0e+00 FUT2
Fasting Glucose 2.12 1 0 0.0 0.00 1.0e+00 CISD2
HDL Cholesterol 3.80 2 2 6.1 0.00 1.0e+00 PSRC1 RP11-138A9.1
LDL Cholesterol 44.77 3 1 3.0 0.00 1.0e+00 FUT2 PSRC1 SH2B3
Lupus 1.53 1 0 0.0 0.00 1.0e+00 SH2B3
Primary Biliary Cirrhosis 3.68 2 1 3.0 0.00 1.0e+00 CISD2 SH2B3
Rheumatoid Arthritis 2.00 1 0 0.0 0.00 1.0e+00 SH2B3
Schizophrenia 1.51 2 0 0.0 0.00 1.0e+00 CISD2 FUT2
Type 2 Diabetes (T2D) 3.34 2 0 0.0 0.00 1.0e+00 CISD2 RP11-138A9.1
Blood Eosinophil Count 14.93 2 2 6.1 0.00 1.0e+00 RP11-138A9.1 SH2B3
Blood Platelet Count 3.26 5 3 9.1 0.77 1.3e-01 CWF19L2 FUT2 MGRN1 SH2B3 SLC22A3
Blood Red Count 3.25 4 2 6.1 0.19 8.1e-01 MC1R MGRN1 RP11-138A9.1 SH2B3
Blood White Count 8.16 5 3 9.1 0.68 2.1e-01 MC1R MGRN1 RP11-138A9.1 SH2B3 TMEM133
Heel T-Score 1.14 3 2 6.1 0.00 1.0e+00 ATG7 PSRC1 TMEM133
BMI 1.23 4 0 0.0 -0.55 4.5e-01 ATG7 CISD2 RP11-138A9.1 SLC22A3
Height 1.09 9 4 12.1 -0.82 6.2e-03 ATG7 FUT2 MC1R MGRN1 PSRC1 SH2B3 SLC22A3 TMEM133 TNNT3
Waist Hip Ratio (WHR) 3.29 6 2 6.1 0.76 8.2e-02 CWF19L2 FUT2 RP11-138A9.1 SLC22A3 TMEM133 TNNT3
Systolic Blood Pressure 17.96 10 8 24.2 0.90 4.7e-04 ATG7 CWF19L2 FUT2 MC1R MGRN1 RP11-138A9.1 SH2B3 SLC22A3 TMEM133 TNNT3
Smoking Status 0.78 1 0 0.0 0.00 1.0e+00 PSRC1
Allergy or Eczema 1.73 2 0 0.0 0.00 1.0e+00 CISD2 SH2B3
Cardiovascular Disease 17.44 11 8 24.2 0.94 1.2e-05 ATG7 CISD2 CWF19L2 FUT2 MGRN1 PSRC1 RP11-138A9.1 SH2B3 SLC22A3 TMEM133 TNNT3
Hypothyroidism (self reported) 10.99 3 1 3.0 0.00 1.0e+00 FUT2 MC1R SH2B3
Type 2 Diabetes (T2D) 3.35 4 0 0.0 0.99 5.5e-03 CWF19L2 RP11-138A9.1 SH2B3 SLC22A3
Lung FEV1/FVC ratio 2.42 4 3 9.1 -0.55 4.5e-01 ATG7 FUT2 PSRC1 TMEM133
Lung FVC 0.89 2 0 0.0 0.00 1.0e+00 CISD2 SH2B3
Neuroticism 1.10 1 0 0.0 0.00 1.0e+00 ATG7
Chronotype (morning person) 1.82 1 0 0.0 0.00 1.0e+00 FUT2
Hair Pigment 70.64 5 2 6.1 0.34 5.8e-01 ATG7 MC1R RP11-138A9.1 SH2B3 TMEM133
Tanning 39.20 3 1 3.0 0.00 1.0e+00 MC1R SH2B3 TMEM133
Hand grip strength (left) 1.61 2 0 0.0 0.00 1.0e+00 MGRN1 TNNT3
Number of treatments/medications taken 8.99 7 4 12.1 -0.97 3.9e-04 ATG7 CISD2 CWF19L2 MGRN1 PSRC1 SH2B3 TMEM133
Average weekly spirits intake 1.67 1 0 0.0 0.00 1.0e+00 FUT2
Sensitivity / hurt feelings 0.98 1 0 0.0 0.00 1.0e+00 CISD2
Hearing difficulty/problems: Yes 1.30 1 0 0.0 0.00 1.0e+00 PSRC1
Relative age of first facial hair 4.16 2 2 6.1 0.00 1.0e+00 ATG7 MC1R
Other serious medical condition/disability diagnosed by doctor 1.56 1 0 0.0 0.00 1.0e+00 PSRC1
Systolic blood pressure, automated reading 12.71 8 6 18.2 -0.91 1.5e-03 ATG7 CWF19L2 FUT2 MC1R MGRN1 SH2B3 TMEM133 TNNT3
Eye problems/disorders: Diabetes related eye disease 2.35 1 0 0.0 0.00 1.0e+00 MC1R
Angina 7.55 3 2 6.1 0.00 1.0e+00 PSRC1 SLC22A3 TMEM133
Medication: Metformin 3.31 2 0 0.0 0.00 1.0e+00 CISD2 RP11-138A9.1
Impedance of leg (right) 1.34 4 0 0.0 -0.65 3.5e-01 ATG7 MC1R PSRC1 TMEM133
Leg fat-free mass (left) 1.32 4 0 0.0 1.00 1.5e-03 PSRC1 SH2B3 SLC22A3 TMEM133
Trunk fat percentage 2.17 4 2 6.1 0.96 4.2e-02 MC1R RP11-138A9.1 SLC22A3 TNNT3
Hand grip strength (right) 1.57 1 0 0.0 0.00 1.0e+00 CWF19L2
Average weekly fortified wine intake 1.74 1 0 0.0 0.00 1.0e+00 MC1R
Fed-up feelings 2.20 1 1 3.0 0.00 1.0e+00 SH2B3
Frequency of unenthusiasm / disinterest in last 2 weeks 1.31 1 0 0.0 0.00 1.0e+00 SH2B3
Relative age voice broke 1.31 1 0 0.0 0.00 1.0e+00 MC1R
Taking other prescription medications 4.09 2 1 3.0 0.00 1.0e+00 CISD2 SH2B3
Age when periods started (menarche) 1.27 1 0 0.0 0.00 1.0e+00 FUT2
Heel bone mineral density (BMD) T-score, automated (left) 1.58 2 0 0.0 0.00 1.0e+00 CISD2 TMEM133
High blood pressure 15.61 10 7 21.2 -0.95 3.3e-05 ATG7 CISD2 CWF19L2 FUT2 MC1R MGRN1 RP11-138A9.1 SH2B3 TMEM133 TNNT3
Hayfever, allergic rhinitis or eczema 1.38 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Atenolol 8.26 5 1 3.0 -1.00 2.7e-04 PSRC1 RP11-138A9.1 SH2B3 TMEM133 TNNT3
Medication: Levothyroxine sodium 9.22 2 1 3.0 0.00 1.0e+00 MC1R SH2B3
Sitting height 1.01 5 0 0.0 0.67 2.2e-01 ATG7 CISD2 FUT2 SLC22A3 TMEM133
High blood pressure (mother) 4.13 3 0 0.0 0.00 1.0e+00 SH2B3 TMEM133 TNNT3
Impedance of leg (left) 1.49 3 0 0.0 0.00 1.0e+00 ATG7 MC1R TMEM133
Leg predicted mass (left) 1.33 4 0 0.0 1.00 1.7e-03 PSRC1 SH2B3 SLC22A3 TMEM133
Trunk fat mass 1.59 3 0 0.0 0.00 1.0e+00 MC1R RP11-138A9.1 SLC22A3
Past tobacco smoking 1.52 1 0 0.0 0.00 1.0e+00 SH2B3
Had menopause 2.31 1 0 0.0 0.00 1.0e+00 MC1R
Forced vital capacity (FVC) 1.02 2 0 0.0 0.00 1.0e+00 CISD2 TMEM133
Heel bone mineral density (BMD) T-score, automated (right) 1.62 2 0 0.0 0.00 1.0e+00 ATG7 TMEM133
Mouth/teeth dental problems 2.40 3 0 0.0 0.00 1.0e+00 CISD2 CWF19L2 FUT2
Heart attack 6.35 3 2 6.1 0.00 1.0e+00 PSRC1 SH2B3 SLC22A3
Allergy 1.44 1 0 0.0 0.00 1.0e+00 CISD2
Diabetes (self-reported) 3.07 3 0 0.0 0.00 1.0e+00 CISD2 CWF19L2 RP11-138A9.1
Medication: Ramipril 7.35 5 1 3.0 -0.98 3.8e-03 CISD2 MGRN1 SH2B3 SLC22A3 TMEM133
Medication: Simvastatin 14.42 6 1 3.0 -0.82 4.5e-02 CWF19L2 FUT2 PSRC1 RP11-138A9.1 SLC22A3 TMEM133
Illnesses of siblings 4.91 3 0 0.0 0.00 1.0e+00 CISD2 SH2B3 TMEM133
Weight 1.15 2 0 0.0 0.00 1.0e+00 SH2B3 SLC22A3
Impedance of arm (right) 2.17 6 1 3.0 0.16 7.6e-01 ATG7 CISD2 PSRC1 RP11-138A9.1 SH2B3 TNNT3
Arm fat percentage (right) 1.08 2 0 0.0 0.00 1.0e+00 RP11-138A9.1 SLC22A3
Trunk fat-free mass 2.06 6 2 6.1 0.75 8.4e-02 MC1R MGRN1 PSRC1 SH2B3 SLC22A3 TMEM133
Hip circumference 2.14 3 2 6.1 0.00 1.0e+00 RP11-138A9.1 SH2B3 SLC22A3
Time employed in main current job 1.29 1 0 0.0 0.00 1.0e+00 MC1R
Alcohol intake versus 10 years previously 1.38 1 0 0.0 0.00 1.0e+00 FUT2
Father's age at death 4.15 2 1 3.0 0.00 1.0e+00 PSRC1 SH2B3
Frequency of tiredness / lethargy in last 2 weeks 2.00 1 0 0.0 0.00 1.0e+00 SH2B3
Number of live births 1.25 1 0 0.0 0.00 1.0e+00 CISD2
Forced expiratory volume in 1-second (FEV1) 1.34 1 0 0.0 0.00 1.0e+00 TMEM133
Mouth/teeth dental problems: Dentures 2.46 2 0 0.0 0.00 1.0e+00 CWF19L2 FUT2
Medication: Ibuprofen (e.g. Nurofen) 1.51 1 0 0.0 0.00 1.0e+00 SLC22A3
Medication: Cholesterol lowering 18.10 4 2 6.1 -0.75 2.5e-01 FUT2 PSRC1 SLC22A3 TMEM133
Medication: Lansoprazole 2.09 1 0 0.0 0.00 1.0e+00 SH2B3
Illnesses of mother 4.03 2 0 0.0 0.00 1.0e+00 SH2B3 TMEM133
Forced expiratory volume in 1-second (FEV1), Best measure 1.14 1 0 0.0 0.00 1.0e+00 TMEM133
Pulse wave Arterial Stiffness index 1.60 1 0 0.0 0.00 1.0e+00 SH2B3
Impedance of arm (left) 2.73 6 1 3.0 0.43 3.9e-01 ATG7 CISD2 MC1R RP11-138A9.1 SH2B3 TNNT3
Arm fat mass (right) 0.89 2 0 0.0 0.00 1.0e+00 RP11-138A9.1 SLC22A3
Trunk predicted mass 2.04 6 2 6.1 0.75 8.5e-02 MC1R MGRN1 PSRC1 SH2B3 SLC22A3 TMEM133
Standing height 1.25 5 3 9.1 1.00 2.7e-04 FUT2 MGRN1 PSRC1 SH2B3 SLC22A3
Seen doctor (GP) for nerves, anxiety, tension or depression 1.41 1 0 0.0 0.00 1.0e+00 MC1R
Hair/balding pattern: Pattern 4 1.38 2 0 0.0 0.00 1.0e+00 ATG7 FUT2
Birth weight of first child 4.14 2 1 3.0 0.00 1.0e+00 ATG7 SH2B3
Peak expiratory flow (PEF) 1.30 1 0 0.0 0.00 1.0e+00 FUT2
Blood clot in the leg (DVT) 2.30 2 0 0.0 0.00 1.0e+00 MC1R SH2B3
Headache pain in last month 1.72 1 0 0.0 0.00 1.0e+00 CISD2
Medication for cholesterol, blood pressure or diabetes 11.68 6 3 9.1 0.95 3.2e-03 CISD2 CWF19L2 FUT2 PSRC1 SH2B3 TMEM133
Gout (self-reported) 2.03 1 0 0.0 0.00 1.0e+00 SH2B3
Hypothyroidism/myxoedema (self-reported) 9.16 2 1 3.0 0.00 1.0e+00 MC1R SH2B3
Medication: Amlodipine 8.30 4 2 6.1 -0.96 4.2e-02 MC1R MGRN1 TMEM133 TNNT3
Birth weight 3.03 2 1 3.0 0.00 1.0e+00 FUT2 SH2B3
High blood pressure (siblings) 5.12 4 0 0.0 -0.98 1.8e-02 MGRN1 SH2B3 TMEM133 TNNT3
Forced vital capacity (FVC), Best measure 0.93 1 0 0.0 0.00 1.0e+00 TMEM133
Body fat percentage 1.91 3 1 3.0 0.00 1.0e+00 MC1R RP11-138A9.1 SLC22A3
Leg fat percentage (right) 1.29 1 0 0.0 0.00 1.0e+00 RP11-138A9.1
Arm fat-free mass (right) 1.74 5 1 3.0 0.70 1.8e-01 CISD2 PSRC1 SH2B3 SLC22A3 TMEM133
Exposure to tobacco smoke outside home 1.92 1 0 0.0 0.00 1.0e+00 SH2B3
Comparative body size at age 10 3.07 3 2 6.1 0.00 1.0e+00 ATG7 FUT2 MC1R
Number of children fathered 2.68 1 0 0.0 0.00 1.0e+00 FUT2
Reason for reducing amount of alcohol drunk: Health precaution 1.69 1 0 0.0 0.00 1.0e+00 CISD2
Pulse wave peak to peak time 1.74 1 0 0.0 0.00 1.0e+00 SH2B3
Medication for pain relief, constipation, heartburn 2.80 2 0 0.0 0.00 1.0e+00 CISD2 PSRC1
Neck or shoulder pain in last month 1.63 1 0 0.0 0.00 1.0e+00 MC1R
Medication: Blood pressure 11.03 7 3 9.1 -0.93 2.4e-03 ATG7 CISD2 CWF19L2 MGRN1 SH2B3 TMEM133 TNNT3
Angina (self-reported) 7.91 3 2 6.1 0.00 1.0e+00 PSRC1 SLC22A3 TMEM133
Migraine (self-reported) 2.00 1 0 0.0 0.00 1.0e+00 CISD2
Medication: Ibuprofen 1.71 1 0 0.0 0.00 1.0e+00 SLC22A3
Medication: Allopurinol 1.95 1 0 0.0 0.00 1.0e+00 SH2B3
Mean time to correctly identify matches 2.96 1 1 3.0 0.00 1.0e+00 SH2B3
Heart disease (mother) 4.31 1 1 3.0 0.00 1.0e+00 SLC22A3
Whole body fat mass 1.39 3 0 0.0 0.00 1.0e+00 MC1R RP11-138A9.1 SLC22A3
Leg fat mass (right) 1.08 2 0 0.0 0.00 1.0e+00 RP11-138A9.1 SLC22A3
Arm predicted mass (right) 1.77 4 1 3.0 0.97 3.1e-02 PSRC1 SH2B3 SLC22A3 TMEM133
Pulse rate, automated reading 1.24 1 0 0.0 0.00 1.0e+00 MGRN1
Alcohol intake frequency. 2.11 2 1 3.0 0.00 1.0e+00 CISD2 FUT2
Comparative height size at age 10 2.03 5 1 3.0 0.76 1.3e-01 FUT2 MC1R PSRC1 SH2B3 SLC22A3
Overall health rating 2.36 4 0 0.0 0.59 4.1e-01 ATG7 CISD2 CWF19L2 MGRN1
Illness, injury, bereavement, stress in last 2 years 1.38 1 0 0.0 0.00 1.0e+00 MC1R
Medication: Aspirin 8.21 4 2 6.1 -0.99 1.0e-02 CWF19L2 PSRC1 SH2B3 SLC22A3
Hypertension (Self-reported) 15.48 11 8 24.2 -0.94 2.3e-05 ATG7 CISD2 CWF19L2 FUT2 MC1R MGRN1 RP11-138A9.1 SH2B3 SLC22A3 TMEM133 TNNT3
Illnesses of father: Heart disease 7.84 3 2 6.1 0.00 1.0e+00 PSRC1 SH2B3 SLC22A3
Smoking status: Previous 1.82 1 0 0.0 0.00 1.0e+00 SH2B3
Forced expiratory volume in 1-second (FEV1), predicted 1.68 1 0 0.0 0.00 1.0e+00 MGRN1
Whole body fat-free mass 1.75 5 1 3.0 0.97 6.6e-03 MGRN1 PSRC1 SH2B3 SLC22A3 TMEM133
Leg fat-free mass (right) 1.36 4 0 0.0 1.00 1.3e-04 PSRC1 SH2B3 SLC22A3 TMEM133
Arm fat percentage (left) 1.23 3 0 0.0 0.00 1.0e+00 MC1R RP11-138A9.1 SLC22A3
Average weekly red wine intake 1.45 1 0 0.0 0.00 1.0e+00 SLC22A3
Mood swings 1.31 1 0 0.0 0.00 1.0e+00 SH2B3
Loneliness, isolation 2.08 1 0 0.0 0.00 1.0e+00 SH2B3
Long-standing illness, disability or infirmity 1.90 1 0 0.0 0.00 1.0e+00 SH2B3
Diabetes diagnosed by doctor 3.93 5 0 0.0 -1.00 3.3e-05 CISD2 CWF19L2 RP11-138A9.1 SH2B3 SLC22A3
Qualifications: nursing, teaching 1.62 1 0 0.0 0.00 1.0e+00 SH2B3
Mouth/teeth dental problems: Mouth ulcers 1.48 1 0 0.0 0.00 1.0e+00 SH2B3
Back pain experienced in last month 1.26 1 0 0.0 0.00 1.0e+00 SH2B3
Mineral and other dietary supplements 1.39 1 0 0.0 0.00 1.0e+00 SLC22A3
Osteoporosis (self-reported) 1.24 1 0 0.0 0.00 1.0e+00 SLC22A3
Medication: Aspirin 8.01 5 2 6.1 -0.98 2.8e-03 CISD2 CWF19L2 PSRC1 SH2B3 SLC22A3
Medication: Gliclazide 2.55 1 0 0.0 0.00 1.0e+00 CISD2
Illnesses of father: None of the above (group 1) 3.85 3 0 0.0 0.00 1.0e+00 SH2B3 SLC22A3 TMEM133
Forced expiratory volume in 1-second (FEV1), predicted percentage 0.91 1 0 0.0 0.00 1.0e+00 TMEM133
Whole body water mass 1.73 5 1 3.0 0.97 6.7e-03 MGRN1 PSRC1 SH2B3 SLC22A3 TMEM133
Leg predicted mass (right) 1.34 4 0 0.0 1.00 1.9e-04 PSRC1 SH2B3 SLC22A3 TMEM133
Arm fat mass (left) 0.99 2 0 0.0 0.00 1.0e+00 RP11-138A9.1 SLC22A3
Number of self-reported non-cancer illnesses 7.69 7 2 6.1 -0.98 1.7e-04 CISD2 CWF19L2 FUT2 MGRN1 PSRC1 SH2B3 TMEM133
Mother's age at death 2.10 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Blood pressure 17.06 11 7 21.2 -0.98 1.4e-07 ATG7 CISD2 CWF19L2 FUT2 MC1R MGRN1 RP11-138A9.1 SH2B3 SLC22A3 TMEM133 TNNT3
Supplements: Fish oil (including cod liver oil) 1.90 1 0 0.0 0.00 1.0e+00 SLC22A3
High cholesterol (Self-reported) 25.44 5 5 15.2 -0.85 6.5e-02 CWF19L2 FUT2 PSRC1 SLC22A3 TMEM133
Medication: Bendroflumethiazide 9.86 8 3 9.1 -0.99 7.0e-07 ATG7 CISD2 CWF19L2 FUT2 MGRN1 SH2B3 TMEM133 TNNT3
Medication: Lisinopril 5.30 2 0 0.0 0.00 1.0e+00 SH2B3 TMEM133
Medication: Atorvastatin 12.83 4 1 3.0 -0.88 1.2e-01 CISD2 FUT2 PSRC1 SLC22A3
Illnesses of father: High blood pressure 3.33 2 0 0.0 0.00 1.0e+00 SH2B3 TMEM133
Ever smoked 1.25 1 0 0.0 0.00 1.0e+00 SH2B3
Basal metabolic rate 1.57 5 1 3.0 0.97 6.3e-03 MGRN1 PSRC1 SH2B3 SLC22A3 TMEM133
Leg fat percentage (left) 1.31 2 0 0.0 0.00 1.0e+00 MC1R RP11-138A9.1
Arm fat-free mass (left) 1.85 4 1 3.0 0.62 3.8e-01 CISD2 PSRC1 SH2B3 SLC22A3
Diastolic blood pressure, automated reading 11.63 7 2 6.1 -0.84 1.9e-02 CISD2 CWF19L2 MGRN1 RP11-138A9.1 SH2B3 TMEM133 TNNT3
Vascular/heart problems diagnosed by doctor 15.78 11 7 21.2 0.93 2.4e-05 ATG7 CISD2 CWF19L2 FUT2 MC1R MGRN1 RP11-138A9.1 SH2B3 SLC22A3 TMEM133 TNNT3
Cholesterol lowering medication 15.32 6 2 6.1 -0.91 1.3e-02 CWF19L2 FUT2 MGRN1 PSRC1 RP11-138A9.1 SLC22A3
Pain experienced in last month 1.53 1 0 0.0 0.00 1.0e+00 SH2B3
Basal cell carcinoma (self-reported) 1.56 1 0 0.0 0.00 1.0e+00 MC1R
Heart attack/myocardial infarction (self-reported) 6.33 3 2 6.1 0.00 1.0e+00 PSRC1 SH2B3 SLC22A3
Deep venous thrombosis (DVT) (self-reported) 1.94 2 0 0.0 0.00 1.0e+00 MC1R SH2B3
Heart disease (siblings) 4.74 3 0 0.0 0.00 1.0e+00 CWF19L2 PSRC1 SLC22A3
Alcohol drinker status: Previous 2.68 1 0 0.0 0.00 1.0e+00 RP11-138A9.1
Impedance of whole body 2.17 6 2 6.1 0.12 8.2e-01 ATG7 CISD2 MC1R PSRC1 TMEM133 TNNT3
Leg fat mass (left) 1.09 2 0 0.0 0.00 1.0e+00 RP11-138A9.1 SLC22A3
Arm predicted mass (left) 1.96 5 1 3.0 0.68 2.0e-01 CISD2 PSRC1 SH2B3 SLC22A3 TMEM133

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 0 0.0000 1.54
GTEx Adipose Visceral Omentum 1 0.0491 1.60
GTEx Adrenal Gland 1 0.0686 1.53
GTEx Artery Aorta 0 0.0000 1.64
GTEx Artery Coronary 0 0.0000 1.50
GTEx Artery Tibial 2 0.0532 1.54
GTEx Brain Caudate basal ganglia 0 0.0000 1.42
GTEx Brain Cerebellar Hemisphere 0 0.0000 1.52
GTEx Brain Cerebellum 0 0.0000 1.54
GTEx Brain Cortex 0 0.0000 1.55
GTEx Brain Frontal Cortex BA9 0 0.0000 1.63
GTEx Brain Hippocampus 0 0.0000 1.38
GTEx Brain Hypothalamus 0 0.0000 1.50
GTEx Brain Nucleus accumbens basal ganglia 0 0.0000 1.60
GTEx Brain Putamen basal ganglia 0 0.0000 1.43
GTEx Breast Mammary Tissue 0 0.0000 1.59
GTEx Breast Mammary Tissue (Male) 0 0.0000 1.60
GTEx Breast Mammary Tissue (Female) 0 0.0000 1.56
GTEx Cells EBV-transformed lymphocytes 0 0.0000 1.55
GTEx Cells Transformed fibroblasts 0 0.0000 1.57
GTEx Colon Sigmoid 0 0.0000 1.56
GTEx Colon Transverse 0 0.0000 1.51
GTEx Esophagus Gastroesophageal Junction 0 0.0000 1.53
GTEx Esophagus Mucosa 1 0.0301 1.54
GTEx Esophagus Muscularis 1 0.0309 1.54
GTEx Heart Atrial Appendage 1 0.0633 1.55
GTEx Heart Left Ventricle 1 0.0654 1.48
GTEx Liver 0 0.0000 1.47
GTEx Lung 0 0.0000 1.57
GTEx Muscle Skeletal 2 0.0692 1.54
GTEx Nerve Tibial 0 0.0000 1.50
GTEx Ovary 0 0.0000 1.58
GTEx Pancreas 0 0.0000 1.57
GTEx Pituitary 0 0.0000 1.55
GTEx Prostate 0 0.0000 1.60
GTEx Skin Not Sun Exposed Suprapubic 1 0.0407 1.59
GTEx Skin Sun Exposed Lower leg 0 0.0000 1.52
GTEx Small Intestine Terminal Ileum 0 0.0000 1.67
GTEx Spleen 0 0.0000 1.57
GTEx Stomach 0 0.0000 1.58
GTEx Testis 0 0.0000 1.55
GTEx Thyroid 0 0.0000 1.55
GTEx Uterus 0 0.0000 1.57
GTEx Vagina 0 0.0000 1.49
GTEx Whole Blood 2 0.1004 1.56
METSIM Adipose 2 0.0434 1.48
NTR Blood 0 0.0000 1.49
ROSMAP Brain Pre-frontal Cortex 0 0.0000 1.59
YFS Blood 2 0.0433 1.44
CommonMind Brain Pre-frontal Cortex 2 0.0372 1.55
TCGA Breast Tumor 1 0.1304 1.59
TCGA Breast Normal 0 0.0000 1.44
TCGA Ovarian Tumor 0 0.0000 1.39
TCGA Prostate Tumor 1 0.0289 1.45